

## Iris Eke

Postdoctoral Research Fellow, Radiation Biology

### Bio

---

#### HONORS AND AWARDS

- Director's Award of Merit, National Cancer Institute (NCI) (2019)
- Hermann Holthusen Award, DEGRO (2015)
- Jack Fowler Award, Radiation Research Society (2011)
- Juliana Denekamp Award, ESTRO (2011)

#### PROFESSIONAL EDUCATION

- ECFMG certificate, ECFMG (2015)
- Doctor of Philosophy, Technische Universitat Dresden (2014)
- Doctor of Medicine, Technische Universitat Munchen (2006)

#### STANFORD ADVISORS

- Edward Graves, Postdoctoral Faculty Sponsor

### Publications

---

#### PUBLICATIONS

- **53BP1/RIF1 signaling promotes cell survival after multifractionated radiotherapy.** *Nucleic acids research*  
Eke, I., Zong, D., Aryankalayil, M. J., Sandfort, V., Bylicky, M. A., Rath, B. H., Graves, E. E., Nussenzweig, A., Coleman, C. N.  
2019
- **The Future of Radiobiology** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*  
Kirsch, D. G., Diehn, M., Kesarwala, A. H., Maity, A., Morgan, M. A., Schwarz, J. K., Bristow, R., Demaria, S., Eke, I., Griffin, R. J., Haas-Kogan, D., Higgins, G. S., Kimmelman, et al  
2018; 110 (4): 329–40
- **Long-term Tumor Adaptation after Radiotherapy: Therapeutic Implications for Targeting Integrins in Prostate Cancer.** *Molecular cancer research : MCR*  
Eke, I., Makinde, A. Y., Aryankalayil, M. J., Reedy, J. L., Citrin, D. E., Chopra, S., Ahmed, M. M., Coleman, C. N.  
2018; 16 (12): 1855–64
- **Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.** *Molecular cancer therapeutics*  
Eke, I., Makinde, A. Y., Aryankalayil, M. J., Sandfort, V., Palayoor, S. T., Rath, B. H., Liotta, L., Pierobon, M., Petricoin, E. F., Brown, M. F., Stommel, J. M., Ahmed, M. M., Coleman, et al  
2018; 17 (2): 355–67
- **Simultaneous #1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.** *Journal of the National Cancer Institute*  
Eke, I., Zscheppang, K., Dickreuter, E., Hickmann, L., Mazzeo, E., Unger, K., Krause, M., Cordes, N.  
2015; 107 (2)
- **Cetuximab attenuates its cytotoxic and radiosensitizing potential by inducing fibronectin biosynthesis.** *Cancer research*  
Eke, I., Storch, K., Krause, M., Cordes, N.

2013; 73 (19): 5869–79

- **EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells.** *Cancer research*  
Eke, I., Schneider, L., Förster, C., Zips, D., Kunz-Schughart, L. A., Cordes, N.  
2013; 73 (1): 297–306
- **Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy.** *The Journal of clinical investigation*  
Eke, I., Deuse, Y., Hehlhans, S., Gurtner, K., Krause, M., Baumann, M., Shevchenko, A., Sandfort, V., Cordes, N.  
2012; 122 (4): 1529–40
- **PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha.** *The Journal of clinical investigation*  
Eke, I., Koch, U., Hehlhans, S., Sandfort, V., Stanchi, F., Zips, D., Baumann, M., Shevchenko, A., Pilarsky, C., Haase, M., Baretton, G. B., Calleja, V., Larijani, et al  
2010; 120 (7): 2516–27